Browse Protease inhibitors topic

Product development subtopic

Articles 1-14 out of 14 article(s) Title Author Type Date Words Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV. Nov 9, 2009 740 Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus. Oct 5, 2009 671 Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia. Jul 30, 2009 1179 Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs. Jun 2, 2009 825 Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting. Apr 27, 2009 844 Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir. Mar 3, 2009 2012 New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection. Clinical report Nov 1, 2008 2159 Phenomix Initiates Phase 1a Clinical Trial of Hepatitis C Protease Inhibitor PHX1766. Oct 28, 2008 372 Medivir: Phase IIa data on TMC435350 in patients with hepatitis C to be presented at AASLD. Sep 24, 2008 740 Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients. Aug 19, 2008 1252 Tipranavir. Apr 1, 2005 91 New protease inhibitor looks promising. Brief Article Mar 26, 2005 145 The hepatitis C drug development pipeline. Raymond, Daniel Sep 22, 2004 2442 Atazanavir expanded access. (Treatment News). Brief Article May 1, 2003 93